Stocks of mid-cap biotech firms rise 15%+ in 6 months after FDA leadership change

Uncertainty over FDA leadership creates short-term volatility, but mid-cap biotech firms with strong pipelines see a sustained 15%+ increase in stock prices by November 2026 as regulatory clarity improves.

Implied probability (Yes)

55%